论文部分内容阅读
目的探讨瑞舒伐他汀对不稳定型心绞痛(UAP)患者内皮功能及血清炎症因子的影响。方法选取UAP患者95例随机分组,观察组48例,给予口服瑞舒伐他汀治疗;对照组47例,给予口服阿托伐他汀治疗。连续治疗3个月,比较两组内皮依赖性舒张变化率(FMD)%、颗粒膜蛋白-140(GMP-140)、血清炎症因子及血脂水平。计量资料采用t检验,P<0.05为差异有统计学意义。结果治疗后,两组血管内皮功能、血清炎症因子及血脂水平均得到改善,但观察组GMP140(5.25±2.38)g/ml、NO浓度(4.69±0.39)mol/L、IFN-γ(281.97±21.02)mol/L、TG(1.59±0.65)g/ml与LDL-C(2.59±0.59)mol/L等改善幅度优于对照组[(7.53±2.62)g/ml、(3.89±0.37)mol/L、(249.51±20.44)mol/L、(2.00±0.70)g/ml、(3.55±0.74)mol/L],差异有统计学意义(均P<0.05)。结论瑞舒伐他汀可有效改善UAP患者内皮功能及血清炎症因子水平。
Objective To investigate the effect of rosuvastatin on endothelial function and serum inflammatory factors in patients with unstable angina pectoris (UAP). Methods Ninety-five patients with UAP were randomly divided into observation group (n = 48) and oral rosuvastatin (n = 47). The control group (n = 47) received oral atorvastatin treatment. Continuous treatment for 3 months, the two groups were compared the rate of endothelium-dependent relaxation (FMD)%, granule membrane protein -140 (GMP-140), serum inflammatory factors and blood lipid levels. Measurement data using t test, P <0.05 for the difference was statistically significant. Results After treatment, the vascular endothelial function, serum inflammatory factors and blood lipid levels were improved in both groups. However, GMP140 (5.25 ± 2.38) g / ml, NO concentration (4.69 ± 0.39) mol / L and IFN-γ (7.52 ± 2.62) g / ml and (3.89 ± 0.37) mol / L, respectively, compared with the control group [21.02] mol / L, TG (1.59 ± 0.65) g / ml and LDL-C /L, (249.51 ± 20.44) mol / L, (2.00 ± 0.70) g / ml, (3.55 ± 0.74) mol / L], the difference was statistically significant (all P <0.05). Conclusion Rosuvastatin can effectively improve endothelial function and serum levels of inflammatory cytokines in UAP patients.